RESUMO
Febuxostat is a xanthine oxidase inhibitor that during the last years has successfully replaced allopurinol treatment in patients with chronic kidney disease (CKD) and hyperuricemia. Several adverse events have been observed during therapy with febuxostat. DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome induced by febuxostat has been poorly described, mainly in patient with CKD who previously developed allopurinol hypersensitivity syndrome. DRESS syndrome is characterized by manifold cutaneous reactions and systemic disorders with potential devastating consequences. The underlying pathogenetic mechanisms remain unidentified, though immune responses are often complicated. P-i concept can partially explain the phenomenon. The role of renal insufficiency appears to be crucial and further investigation is required. The present article describes the case of a CKD patient that developed febuxostat-related DRESS syndrome.
Assuntos
Síndrome de Hipersensibilidade a Medicamentos/etiologia , Febuxostat/efeitos adversos , Supressores da Gota/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Insuficiência Renal Crônica/tratamento farmacológicoRESUMO
Prednisolone was administered as an anti-inflammatory for 7 consecutive days in 11 dogs with leishmaniasis (CL group) and 5 clinically normal dogs (control group). After a 15-day wash-out phase, the same medication was given as an immunosuppressive for another 7-day period. In both animal groups and experimental periods an overall significant increase of serum iron and transferrin saturation was noted. Serum copper showed a significant increase during the anti-inflammatory period in the control group and a significant decrease during the immunosuppressive period in the CL group. No differences or changes of any kind regarding bone marrow hemosiderin were found between the 2 groups either before or after the end of both experimental periods. The only change noticed in the hematocrit values was a significant decrease in the control group after the end of the anti-inflammatory period. Based on these findings the use of prednisolone cannot be recommended and, if contemplated, should be carefully monitored, especially at an immunosuppressive dosage, because it may promote parasite replication through the induction of increased serum iron levels and hypocupremia.
Assuntos
Cobre/sangue , Doenças do Cão/sangue , Glucocorticoides/uso terapêutico , Ferro/sangue , Leishmania infantum , Leishmaniose Visceral/veterinária , Prednisolona/uso terapêutico , Animais , Análise Química do Sangue/veterinária , Doenças do Cão/tratamento farmacológico , Cães , Feminino , Glucocorticoides/farmacologia , Hematócrito/veterinária , Hemoglobinas/análise , Leishmaniose Visceral/sangue , Leishmaniose Visceral/tratamento farmacológico , Masculino , Prednisolona/farmacologia , Distribuição AleatóriaRESUMO
Two novel chromosomal translocations were identified in 2 patients with chronic lymphocytic leukemia (CLL). Case 1: 60 year-old male, stage Rai 0/Binet A, with mutated immunoglobulin heavy (IgH) and lambda (Iglambda) light chain genes; karyotype: 46, XY, t(9;12)(q12;p11) [3]/ 46, XY [22]. Case 2: 56 year-old male, stage Rai 2/Binet B, with mutated IgH and unmutated Iglambda genes; karyotype: 46, XY, add(10)(q26), t(13;18)(q14;q21) [8]/ 46, XY [27]. Although both translocations are novel, the involved breakpoints (especially 13q14 and 18q21) have been reported to participate in various aberrations in CLL patients. Aberrations affecting bands 9q12 and 12p11, as in case 1, are generally rare.
Assuntos
Cromossomos Humanos/genética , Leucemia Linfocítica Crônica de Células B/genética , Translocação Genética/genética , Humanos , Cariotipagem , Masculino , Pessoa de Meia-IdadeRESUMO
Myelodysplastic syndrome (MDS) in patients treated for acute promyelocytic leukemia (APL) is a rare event. We describe a patient with APL who developed MDS 40 months after entering complete remission (CR). Karyotypic analysis revealed monosomy 5 and 7, which are cytogenetic changes usually occurring after the use of alkylating agents. The patient had received only anthracyclines as potential leukemogenic drugs. A review of the literature on t-AML/MDS occurring after successful therapy for APL showed three similar cases. These observations suggest that anthracyclines may cause t-AML/MDS similar to that induced by alkylating agents.
Assuntos
Antibióticos Antineoplásicos/efeitos adversos , Leucemia Promielocítica Aguda/tratamento farmacológico , Síndromes Mielodisplásicas/induzido quimicamente , Segunda Neoplasia Primária/induzido quimicamente , Antibióticos Antineoplásicos/uso terapêutico , Cromossomos Humanos Par 5 , Cromossomos Humanos Par 7 , Evolução Fatal , Feminino , Doença Enxerto-Hospedeiro/tratamento farmacológico , Humanos , Terapia de Imunossupressão , Leucemia Mieloide Aguda/etiologia , Leucemia Promielocítica Aguda/terapia , Pessoa de Meia-Idade , Monossomia , Síndromes Mielodisplásicas/genética , Síndromes Mielodisplásicas/patologia , Segunda Neoplasia Primária/genética , Segunda Neoplasia Primária/patologia , Transplante de Células-Tronco de Sangue Periférico/efeitos adversos , Transplante HomólogoRESUMO
Several experimental autoimmune diseases (AID), including allergic encephalomyelitis, ie the multiple sclerosis (MS) model, respond to TBI and chemotherapy followed by BMT. Remissions of AID may also occur in patients with concomitant malignancies treated with allogeneic or autologous BMT. These observations have emphasized the possibility of treating AID with high-dose therapy and haematopoietic stem cell transplantation (HSCT). In a phase I/II pilot study, 15 patients with progressive MS were treated with BEAM followed by autologous blood SCT and antithymocyte globulin (ATG). Patients were severely disabled, with median EDSS and SNRS scores of 6 (5-7.5) and 42 (33-62), respectively. Cyclophosphamide (4 g/m2) and G/GM-CSF (5 microg/kg/day) were used for stem cell mobilization, which caused no neurotoxicity. On days +1 and +2, ATG (2.5-5 mg/kg) was given for in vivo T cell-depletion. Allergy (93%) and infections (87%) were the principal toxic complications. Mild, transient, neurotoxicity was observed in six patients in the immediate post-transplant period. The median follow-up time is 6 months (6-18). Durable neurologic improvements have been detected on both the EDSS (7/15) and SNRS (15/15) systems. One patient worsened at 3 months and two have relapsed. Autologous HSCT appears feasible in MS; it does not aggravate disability and seems to offer a clinical benefit. However, these observations need confirmation and long-term outcomes will show if benefits counterbalance toxicity and cost.